Italia markets close in 4 hours 14 minutes

Perspective Therapeutics, Inc. (CATX)

NYSE American - NYSE American Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,4700+0,0400 (+2,80%)
Alla chiusura: 04:00PM EDT
1,4500 -0,02 (-1,36%)
Dopo ore: 07:50PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,4300
Aperto1,4500
Denaro0,9600 x 4000
Lettera1,5300 x 3000
Min-Max giorno1,3300 - 1,4700
Intervallo di 52 settimane0,2100 - 1,6000
Volume5.025.333
Media Volume3.956.435
Capitalizzazione862,766M
Beta (5 anni mensile)1,57
Rapporto PE (ttm)N/D
EPS (ttm)-0,1400
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A1,57
  • GlobeNewswire

    Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

    SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 (clinicaltrials.gov identifier NCT05655312), its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma. “We are encouraged by the pace of enrollment in the trial which we believe is indicativ

  • GlobeNewswire

    Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium

    SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors Summary: This presentation

  • GlobeNewswire

    Perspective Therapeutics’ Cesium-131 Featured at the American Society for Radiation Oncology’s Annual Conference

    SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long-term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer, as well as preliminary long-term data of Cesium-131 utilized in salvage tr